Millipore, a life-science provider of technologies and services for bioscience research and biopharmaceutical manufacturing, has introduced a next-generation virus-clearance solution.
The Viresolve Pro Solution features a patent pending membrane, a newly designed device format, highly sensitive performance tests and a comprehensive range of services and virus-clearance expertise.
Manufacturers of biotech products derived from recombinant cell lines or human plasma are aware of the risk of virus contamination that requires the most robust virus-clearance solution available.
Paul Chapman, vice-president of downstream processing at Millipore Corporation, said: 'This product has been developed through very close collaboration with key innovative biotech players in the US and Europe.' Based on a dual-layer polyethersulfone (PES) membrane designed to simultaneously deliver high-parvovirus lapine rotavirus (LRV), capacity and flux, the Viresolve Pro device formats are intended to enable productivity gains from process development to full-scale production.
Testing performed with Viresolve Pro devices has shown capacities in excess of 3,000g/m2 in 75 per cent of all molecules tested.
All of the device formats are fully disposable and are shipped gamma-irradiated.
Marty Siwak, director of the Biomanufacturing Science Network at Millipore Corporation, said: 'The intersection of high tiers, evolution of process platforms and increasing focus on the cost of goods sold spell out a need for robust high-capacity unit operations.'
